The aim of this study is to evaluate the efficacy and tolerability of Lonquek which is a
pegylated (long-acting) version of Filgrastim recombinant human G-CSF (G-CSF) in mobilizing
sufficient number of stem cells for autologous stem cell transplantation in patients with
lymphoma and multiple myeloma.